Chemoresistance As a Function of the Pretherapy Tumor Burden and the Chemotherapy Regimen Administered: Differences Observed With 2 Current Chemotherapy Regimens for Advanced Hodgkin Lymphoma

Micro-Abstract Chemoresistance can be disclosed by incomplete response or early relapse. The tumor burden of Hodgkin lymphoma was assessed in 115 patients treated with ABVD and 107 with BEACOPP and demonstrated to be the best predictor of resistance. For the same tumor burden ABVD has higher risk of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2011-10, Vol.11 (5), p.396-402
Hauptverfasser:	Gobbi, Paolo G, Valentino, Francesco, Bassi, Emilio, Coriani, Chiara, Merli, Francesco, Bonfante, Valeria, Marchianò, Alfonso, Gallamini, Andrea, Bolis, Silvia, Stelitano, Caterina, Levis, Alessandro, Federico, Massimo, Angrilli, Francesco, Di Giulio, Giuseppe, Corazza, Gino R
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bleomycin Chemoresistance Chemotherapy Clinical trials Computed tomography Cyclophosphamide Dacarbazine Doxorubicin Drug Resistance, Neoplasm - drug effects Etoposide Female Hematology, Oncology and Palliative Medicine Hodgkin Disease - diagnosis Hodgkin Disease - drug therapy Hodgkin Disease - pathology Hodgkin lymphoma Hodgkin's disease Humans Male Middle Aged Myeloma Neoplasm Staging Positron-Emission Tomography Prednisone procarbazine Prognosis Regression analysis Remission Retrospective Studies Risk factors Surface area Treatment Outcome Tumor burden Tumor Burden - drug effects Tumors Vinblastine Vincristine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract Chemoresistance can be disclosed by incomplete response or early relapse. The tumor burden of Hodgkin lymphoma was assessed in 115 patients treated with ABVD and 107 with BEACOPP and demonstrated to be the best predictor of resistance. For the same tumor burden ABVD has higher risk of resistance than BEACOPP and it should be considered in the choice of treatments.
ISSN:	2152-2650 2152-2669
DOI:	10.1016/j.clml.2011.04.008